Protocol Ledger

NCT06468033 · Phase III · ACTIVE NOT RECRUITING

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Interventional Phase III clinical trial protocol NCT06468033 sponsored by PharmaEssentia in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-18 Enrollment: 160 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06468033
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)160 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06468033
Protocol FieldVerified Registry Value
NCT IdentifierNCT06468033
Consolidated Lead SponsorPharmaEssentia
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment160 participants (ACTUAL)
Registered Start Date2025-07-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI